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An accurate understanding of the mechanisms underlying an individual’s response to rt-PA treatment is critical to improve
stroke patients’ management. We thus reviewed the literature in order to identify biochemical and genetic factors that have been
associated with safety and eﬃcacy of rt-PA administration after stroke.
1.Introduction
Stroke is a complex disease and is considered to be the main
cause of adult dependency and the third cause of death
in industrialized countries. Ischemic stroke, deﬁned by the
obstruction of a blood vessel impairing cerebral blood ﬂow,
accounts for nearly 87% of all stroke cases. The only drug
approved for the treatment of an acute ischemic stroke is
alteplase or recombinant tissue plasminogen activator (rt-
PA). The purpose of rt-PA administration is to provoke
timely recanalization of the occluded vessel, which in turn
restoresbloodﬂow intheischemicarea, andhelpspreserving
the ischemic penumbra. rt-PA is a drug manufactured using
recombinant technologies based on the tissue plasminogen
activator (t-PA), an endogenousserine protease found in en-
dothelial cells and involved in the breakdown of blood clots.
This enzyme is responsible for the activation of plasminogen
atan intravascularlevelandthe catalyzationofitsconversion
into plasmin, which is the main protein implicated in clot
lysis. Stroke guidelines recommend rt-PA administration no
later than 4.5 hours after symptoms onset [1–6], based on
the fact that, beyond this time point, adverse risks might
outweigh beneﬁts [7, 8].
Despite the great beneﬁts of thrombolysis for stroke
patients [8], only 14.3% of them are currently treated with
this approach [9]. This low rate is mainly due to the fact
that most patients arrive beyond the recommended time
window for treatment to their to stroke center, but also to
the adverse eﬀects associated with rt-PA administration. The
main concerns about rt-PA administration are its safety and
eﬃcacy. On one hand, the safety issue refers to the possible
occurrence ofsevere hemorrhagic transformation (HT) after
rt-PA infusion, which is a multifactorial phenomenon in
which ischemic brain tissue converts into a hemorrhagic le-
sion with blood-vessel leakage, blood extravasation, and
brain damage. There are several subtypes of HT, and they
can be classiﬁed depending on their severity. Hemorrhagic
infarction is usually considered as a relatively minor compli-
cation,while parenchymal hemorrhage (PH)isconsideredto
be the most serious case of HT, involving large hematomas
and usually causing a massive eﬀect. Symptomatic intrac-
erebral hemorrhages (SICHs), such as most PH, involve a
neurological deterioration of four or more points on the
National Institutes of Health Stroke Scale (NIHSS) score.
They aﬀect 2% to 6% of treated patients when evaluated at
36 hours and increase in frequency as late as the treatment2 Stroke Research and Treatment
is given [1–4]. SICHs result in poor clinical outcome and
hamper eﬀorts to extend the therapeutic window. On the
other hand, the eﬃcacy of rt-PA administration refers to
the speed at which the cerebral artery can be recanalized,
but also to the absence of reocclusion after a successful
recanalization, both relating to neurological and functional
outcome. Current knowledge on the occurrence of vessel
recanalization shows that 30% to 36% of patients treated
with rt-PA achieve complete recanalization, and up to 70%
experience some degree of partial recanalization, although
33.8% to 40% of patients do not recanalize [10–13].
A better understanding of the biological and genetic
factorsassociatedwithapatient’sresponsetort-PAisneeded,
because it might be useful in order to minimize the risk of
SICH. Moreover, the identiﬁcation of patients who arrived
beyond the therapeutic time window, but present a low risk
of complications and therefore might beneﬁt from rt-PA
treatment, might be useful, as could be the identiﬁcation
of patients presenting resistance to treatment. Indeed, these
patients would probably not recanalize but could beneﬁt
from more invasive treatments such as intra-arterial rt-PA
administration, mechanical thrombectomy, or the addition
of sonothrombolyis to standard therapies. Finally, under-
standing the underlying mechanisms associated with the
individual response to rt-PA would help physicians adjust
drug doses accordingly. The aim of this study was thus to
perform a review of the literature, to compile the results
observed for blood biomarkers and genetic factors, which
have been associated with eﬃcacy and safety of rt-PA
treatment in stroke patients.
2.BiomarkersAssociated withrt-PA Treatment
A biomarker is a characteristic that is objectively measured
and evaluated as an indicator of normal biologic processes,
pathogenic processes, or pharmacologic responses to a
therapeutic intervention [14]. The use of biomarkers is
becoming a standard practice in some areas of medicine for
decision-making processes, and some of them are already
widely accepted. A good biomarker should ideally be speciﬁc
and sensitive, detectable in samples readily available (urine,
blood, hair or exhaled air), detectable rapidly and at low
cost, should allow preventive measures and should be
ethically accepted. Regarding thrombolytic therapy, plasma
and serum biomarkers are the most commonly used in
reported studies. Blood samples are usually collected before
ﬁbrinolytictherapyorduringthehoursimmediately afterrt-
PA infusion when temporal proﬁles want to be studied.
2.1. Biomarkers Associated with Loss of Blood-Brain Integrity
and Hemorrhagic Transformation. HT, and speciﬁcally
SICH, is the most feared complication of rt-PA admin-
istration. It is thus really important to understand the
mechanisms underlying this pathological condition. The
National Institute of Neurological Disorders and Stroke
(NINDS) study revealed that the risk of developing an SICH
was 6% in rt-PA-treated patients compared to only 1% in
the placebo group [1]; results have been later conﬁrmed by
other studies [4, 15]. Over time, the therapeutic window has
been established up to 4.5 hours after symptoms onset [5–
7]. The advent of useful biomarkersto identify those patients
with higherHTriskiscrucialtosafely widenthattherapeutic
window andallow morepatientstobeneﬁtfrom thistherapy.
Loss of integrity of the blood-brain barrier (BBB)
resulting from ischemia and reperfusion is believed to be
a precursor of HT and poor outcome after stroke. The
BBB protects the brain against molecules and pathogens
circulating through the blood stream. This specialized neu-
rovascular interface comprisesthe endothelialtight junction,
basal lamina, and astrocytic end feet. BBB leakage and blood
constituents extravasation to the cerebral parenchyma are
highly correlated with loss of basal lamina. Thus, main-
taining basal lamina integrity is a key challenge to prevent
hemorrhagic complications and brain damage induced by
this phenomenon. Recent studies have implicated matrix
metalloproteinases (MMPs) in this process, since they attack
the basal lamina and later result in damage to the ultrastruc-
ture of the microvasculature. Peripheral blood neutrophils
inﬁltration, which is closely related to the basal lamina
collagen IV degradation and BBB breakdown, has been
demonstrated in infarct areas [16]. Neutrophils use MMPs
for their migration, and rt-PA has been shown to promote
neutrophils degranulation and MMP-9 release in vitro [17].
MMPs are zinc-dependent endopeptidases that have a
clear role in diverse cellular processes such as proliferation,
apoptosis and tissue morphogenesis, and are also involved
in most physiological processes involved in the extracellular
matrix renewal. In addition to this role in repairing and
remodelling, the presence of elevated levels of MMPs has
been associated with tissue destruction in a wide variety of
pathological processes. Some studies have implicated MMP-
2 and MMP-9 in cerebral ischemia [18–21]. When MMPs
are overexpressed, they degrade substrates of the blood
brain barrier, increase edema, inﬂammatory cell inﬁltration,
and damage the brain parenchyma after stroke [22–24].
Moreover, high concentrations of MMP-9 (>97ng/mL) in
plasma before rt-PA treatment have been shown to predict
HT occurrence (PH: 270.2 ± 87.8ng/mL, non-HT: 126.3 ±
127.5ng/mL; P = .047) [21, 25]. In fact, an almost linear
relationship between the concentrations of MMPs and the
severity of HT was observed (HI-1 = 37.4ng/mL; HI-2 =
111.0ng/mL; PH-1 = 202.5ng/mL; PH-2 = 337.8ng/mL). In
that study, a cut-oﬀ point for MMP-9 of 191.3ng/mL had
a sensitivity of 100% and a speciﬁcity of 78% to detect the
presence of PH with a positive predictive value of 67% and a
negative predictive value of 100% [21]( Table 1).
Fibronectin, a component of the basement membrane,
is an adhesive dimeric glycoprotein that promotes cell-to-
cell and cell-to-matrix interactions and is therefore involved
in wound healing. High levels of cellular ﬁbronectin (c-
Fn) could be associated with endothelial damage. In fact,
plasma c-Fn levels have been reported to be increased in
patients with vascular injury [26]. A study suggested that c-
Fn levels higher than 3.6μg/mL in plasma, measured before
rt-PA administration, could predict the development of HI-
2 and PH with a sensitivity and negative predictive value of
100% [27]. Later, a multicentre and prospective study foundStroke Research and Treatment 3
Table 1: Proteins associated with safety and eﬃcacy of rt-PA.
Protein n Measurement Concentration OR (95% CI) Prediction Reference
Hemorrhagic transformation
MMP9 41 Baseline ≥140ng/mL 9.62
(1.31–70.26) HT Montaner et al. [21]
MMP9 250 Baseline ≥140 ng/mL 16 (3 to 79);
P<. 001 HT Castellanos et al. [25]
c-Fn 87 Baseline ≥3.6μg/mL 2.1 (1.3 to 3.4);
P = .002 HI-2/PH Castellanos et al. [27]
MMP-9/c-Fn 134 Baseline
MMP-9 ≥
140ng/mL/c-Fn ≥
3.6μg/mL
67 (6.9–649);
P<. 001 HT Castellanos et al. [28]
VAP-1/SSAO 141 Baseline Activity >
2.7pmol/min·mg
5.84
(2.16–15.80);
P = .001
HT/ND Hern´ andez-Guillamon
et al. [29]
PAI-1/TAFI 77 Baseline
TAFI > 180%
PAI-1 <
21.4ng/mL
12.9; (1.41 to
118.8); P = .02
12.75 (1.17 to
139.2); P = .04
HT Ribo et al. [30]
APC 119 2hafter
rt-PA APC > 176%
25.19;
(4.76–133.19);
P = .0001
PH Mendioroz et al. [31]
S100B 275 Baseline S100B > 0.14 2.80 (1.40 to
5.62); P = .004 HT Foerch et al. [32]
Recanalization
PAI-1 77 Baseline PAI-1 > 34ng/mL Poor Rec. Ribo et al. [33]
TAT 85 Post rt-PA <24μg/mL
6h o u r :6 . 4
(1.5–26.5);
P = .011
Better rec. Fernandez-Cadenas
et al. [34]
HT: hemorrhagic transformation, PH: parenchymal hemorrhagic, ND: neurological deﬁcit, Rec.: recanalization, sens: sensitivity,spec: speciﬁcity.
that baseline serum c-Fn and MMP-9 concentrations were
signiﬁcantly higher in patients with HT and PH [28]. They
also observed a sensitivity of 100%, a speciﬁcity of 60%, and
positive and negative predictive values for PH using c-Fn
levels ≥3.6μg/mL of 20% and 100%, respectively, whereas
corresponding values were 92%, 74%, 26%, and 99% for
MMP-9 levels ≥140ng/mL. When biomarkers were found
above these cut-oﬀ points, the speciﬁcity increased up to
87%,andthepredictedpositivevalueupto47%.Theauthors
hypothesized that c-Fn could be a useful marker to identify
the patients at greater risk of suﬀering an SICH (Table 1)
[28].
These results suggest that MMPs and c-Fn are definitely
involved in the occurrence of symptomatic bleedings, al-
though they should be considered cautiously because their
power on HT risk prediction is still unknown. The positive
predictivevalueofthese biomarkersmight notbe suﬃciently
high to be used in a clinical setting. Moreover, the sample
size in these studies was small, thus requiring the study of
HT, and not only symptomatic ones, which are the most
relevant due to their fatal consequences. A large sample size
is needed to study SICH due to its low prevalence in stroke
patients.Thereforetheseresultsshouldbereplicatedbyother
groups, with larger sample size and boundedto SICH,before
they could be generalized and useful for clinical practice.
Assuming that markers that predict PH such as MMP-9 and
ﬁbronectin might be also interesting, we have recalculated
the LR (+) and (−) for the article of Castellanos et al.,
considering a prevalence of the disease, that is, PH = 8.96%
(N = 12 PH, N = 122 non PH), the PRE-TEST probability
is then 8.96%, with their data the Likelihood ratio +6.99,
and the Likelihood ratio −0.09, so with that data the POST-
TEST probability = 40% for the presence of PH and 1% for
its absence. Therefore, even for the prediction of PH those
markersarenotusefultoruleoutpatientsfromthetreatment
and probablytheymight onlybe used torulein patientswith
a very low risk of bleedings.
One of the most recent and important ﬁndings in
stroke biomarkers is the identiﬁcation of vascular adhesion
protein-1 (VAP-1) as a predictor of HT after rt-PA. VAP-1
is an ectoenzyme that belongs to the semicarbazide-sensitive
amine oxidase (SSAO) family. It is expressed in endothelial
cells, regulates leukocyte traﬃcking, including neutrophils
and thus an association with BBB disruption was hypothe-
sized. In addition, VAP-1 is associated with the extravasation
under inﬂammatory conditions, and it increases ischemic
brain injury, due to its function as an SSAO, by producing
toxic metabolites [29]. Some studies have found abnormally
high plasma VAP-1/SSAO activity in patients with some
vascularorinﬂammatory conditions[35,36].Anotherrecent
study showed that high levels of plasma VAP1/SSAO activ-
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predicted the appearance of HT (OR (5.84 (2.16–15.80),
P = .001)), the occurrence of PH (OR (11.18 (2.19–56.93),
P = .004)) and neurological deterioration [29]( Table 1).
VAP-1/SSAO > 2.7pmol/min·mg had a sensitivity of 87.5%,
a speciﬁcity of 61.3%, a positive predictive value of 62.26%
and a negative one of 97.4%. They also observed that
delayed rt-PA cotreatment with the vap-1/SSAO inhibitor
semicarbazide, in an animal model, reduced the infarct
volume(8.73%(0–50%)semicarbazidegroupversus35.46%
(8.43–45.83%) saline group; P = .036) and the presence
of bleedings [18% versus 43%, resp.), so they suggested
that the use of SSAO inhibitors could be an adjuvant
treatment to rt-PA, blocking the leukocyte migration eﬀect
that might prevent rt-PA-induced neutrophil degranulation.
A potentially valuable strategy to study SICH prevention
mechanisms would be to target the moleculesinvolved in the
inﬁltration of neutrophils in the ischemic areas such as VAP-
1/SSAO. Nevertheless, more research should be performed
to validate these results. Larger patients groups are needed
in order to study the risk of SICH and clinical trials should
be performed to test this or other adjuvant therapies in the
future. On the other hand, the positive predictive value for
VAP-1/SSAO was higher than those observed with MMP-
9 and c-Fn (62.26% versus 26% and 20%, resp.) which
indicates that VAP-1/SSAO measured before rt-PA would be
a better candidate to predict PH. Maybe in the future the
combination of several biomarkers would be the solution to
increase the predictive value and to be used in daily clinical
practice.
Interestingly, VAP-1/SSAO is also linked to oxidative
stress, and we have recently described that some oxidative
stress related markers such as malondialdehyde (MDA) are
indeed related to the appearance of HT following tPA
treatment [37].
2.2. Biomarkers Associated with Fibrinolysis and Coagulation
Homeostasis. Plasminogen activator inhibitor-1 (PAI-1) is
the main endogenous inhibitor of rt-PA. It binds directly to
rt-PA and inhibits its ﬁbrinolytic action by a stechiometric
action 1:1. PAI-1 has been consistently associated with
acute stroke [38–40] and with other cerebrovascular diseases
[41, 42]. Thrombin-activable ﬁbrinolysis inhibitor (TAFI)
is an indirect ﬁbrinolysis inhibitor. It is activated by the
complex thrombin/thrombomodulin or plasmin, which has
an inhibitory eﬀect on ﬁbrinolytic processes. TAFI cleaves
n-terminal lysine residues oﬀ ﬁ b r i n( i tm a yp o s s i b l ya l s o
split from ﬁbrin monomers) and thereby prevents rt-PA and
plasminogen bind. Elevated TAFI levels have been reported
as a risk factor for stroke [43, 44]. Regarding thrombolytic
treatment, some in vitro studies and animal models have
shown thatthe inhibition ofTAFIacceleratesclotdissolution
by rt-PA [45–47]. Ribo et al. found that levels of PAI-1 <
21.4ng/mL and TAFI levels >180% in plasma, measured
before rt-PA administration and determined by enzyme-
linked immunosorbent assays (ELISAs), predicted SICH
occurrence (75% positive predictive value, predictive value
negative 97.6%) [30]( Table 1) .H o w e v e r ,t h es a m p l es i z e
studiedwassmall,andtherearenootherstudiesthatsupport
these results.
Recently, the activated protein C (APC), a plasma serine
protease with an anticoagulant activity and a wide range
of cytoprotective functions [48–51], has shown to prevent
bleeding induced by rt-PA in vivo in animal models and to
reduce the expression of MMP-9 in human brain endothelial
cells in vitro [52]. Thus, it was suggested that the coad-
ministration of this protein with rt-PA could be useful to
expand the therapeutic window of rt-PA [53]. However,
since the APC is a protein with an anticoagulant action,
ischemic stroke patients treated with this drug could suﬀer
bleeding complications [54]. Recently, an association of APC
concentration with bleeding complications and mortality
after rt-PA treatment has been revealed. Two hours after
starting treatment, APClevelsover176%predicted PHwhile
APC levels over 157% predicted mortality [31]( Table 1). In
thisstudy,theauthorspointedoutthathighAPClevelscould
beacauseorevenaconsequenceofposteriorHToccurrence.
However, APC is not a useful biomarker since its association
with HT was observed 2 hours after and not before rt-PA
administration.
2.3. Biomarkers Associated with Recanalization. Regarding
treatment eﬃcacy, several molecules have been associated
with the revascularization of brain vessels or recanalization.
The most important are associated with the ﬁbrinolysis
and coagulation systems. An increase in PAI-1 activity has
been reported in stroke patients, as compared with controls
(11.6U/mL versus 8.8U/mL, P<. 0001) [40], and patients
with higher concentrations of PAI-1 in plasma (PAI-1 >
34ng/mL), previous to rt-PA administration, showed poor
recanalization rates [33]. The main endogenous inhibitor of
plasmin, which is a key enzyme for ﬁbrinolysis, the alpha-
2-antiplasmin, was also found to be involved, albeit with
contradictory results, in recanalization after rt-PA. A study
showed that patients who did not recanalize within the six
ﬁrst hours after ﬁbrinolytic treatment had lower plasma
levels of alpha-2-antiplamin than those who did (96.5%
versus 87.5%, resp., P = .023) and also for functional TAFI
(91.7% versus 104.4%, P = .039) [58]. But a later study of
t h es a m eg r o u pf o u n dn oa s s o c i a t i o n[ 59]. The Thrombin-
Antithrombin (TAT) complex can be used as an indirect
measure of thrombin concentration in plasma, which is
considered to be the central enzyme of the coagulation
cascade. Thrombin exerts opposite eﬀects and is a key factor
in the regulation of haemostasis [60]. A report described
how high levels of TAT in plasma measured 24 hours after
rt-PA infusion predicted poor outcome three months after
an ischemic stroke [61]. Moreover, a recent study showed
that low baseline plasmatic levels of TAT were associated
with better rates of complete artery recanalization one hour
after ﬁbrinolytic treatment (OR = 24.8 IC 95% 1.4–434.8;
P = .028), as well as 2 hours (OR = 6.3 IC 95% 1.5–27;
P = .014) and 6 hours (OR = 6.4 IC 95% 1.5–26.5; P =
.011) [34]( Table 1). This study did not conﬁrm a signiﬁcant
association between TAT levels and mortality at 3 months,
but the mechanism involved in this poor outcome couldStroke Research and Treatment 5
Table 2: Polymorphismsand genes associated with rt-PA safety or eﬃcacy.
Polymorphism/Gene Measure % P-value OR (95% CI) Prediction Reference
Hemorrhagic transformation
Val34Leu FXIII gene DNA leu: 11.9% severe
HT Val: 3.4%; P<. 05 2.95 (1.07 to 8.11);
P = .035 SICH Gonz´ alez-Conejero et al.
[55]
Recanalization
I/D ACE gene DNA DD = 69.2%, ID
+I I= 31.6%; P = .002 4.3 (1.35–13.49) Good Rec. Fernandez-Cadenas
et al. [56]
Thr325Ile TAFI gene DNA
Thr/Thr: 42%,
Thr/Ile: 48%,
Ile/Ile: 13.3%;
P<. 05 N/A Low rec. Fernandez-Cadenas
et al. [57]
Thr325Ile (Hm) + G4
PAI-1 TAFI gene DNA
Ile/Ile + 4G:
7.1%; other:
45.9%;
P<. 05 11.06 (1.36–89.8),
P = .025 Low rec. Fernandez-Cadenas
et al. [57]
Polymorphisms and genes associated with rt-PA safety or eﬃcacy. HT: hemorrhagic transformation. Rec.: recanalization.
be the absence of recanalization rather than the increase in
HT rates, since it is well known that the absence of vessel
reopeningisassociatedwithworseneurologicaloutcomeand
mortality [62].
2.4. Biomarkers with Other Modes of Action. Finally, S100B,
a calcium-binding protein, has been reported to be a serum
marker of BBB dysfunction [63]. It has regulatory functions
at an intracellular and extracellular level, related to cell mi-
gration and proliferation, apoptosis inhibition, and cell dif-
ferentiation, has been associated with HT occurrence. S100B
is important in the activation of astrocytes in the course of
brain damage and neurodegenerative processes [64]. It has
been associated with some cerebrovascular diseases, such as
hypoxic-ischemic brain injury or intracerebral hemorrhage.
High concentrations of this protein (S100B > 0.21μg/L) are
associated with an increased risk of HT after thrombolytic
therapy (2.80 (1.40 to 5.62; P = .004)) [32]( Table 1). They
found that a cut-oﬀ point of 0.23μg/L provided a speciﬁcity
of 0.82 for prediction of PH-2 (positive predictive value
of 12%, a negative predictive value of 97%, AUC = 0.661,
P = .01), but the clinical usefulness of this biomarker is
not clear due to its low positive predictive value. In any case,
S100B seems to reﬂect BBB disruption in the acute phase of
ischemic stroke, although it is not speciﬁc enough to show
BBB leakage extension and reﬂect, therefore, the degree of
HT.
Also, urinary micro- and macroalbuminuria, that indi-
catesdysfunctionofvascularendothelium,hasbeenreported
to independently predict hemorrhagic transformation in
acute ischemic stroke and might therefore be added to the
list of pathways involved in the process of HT [65].
3.Pharmacogeneticsof rt-PA
Pharmacogenetics is a discipline that studies the response
of an organism, depending on its genetic background, to a
given drug. It has emerged as a strong tool to individualize
therapies with the purpose of preidentifying patients who
willbetterrespondtoagiventreatmentortochoosethemost
appropriate dose or type of drug needed for each patient
[66]. Many eﬀorts are being made to identify genetic
biomarkers that could be used to predict the response of an
individual patient to ﬁbrinolytic therapy.
3.1. Genetic Predictors of Hemorrhagic Transformation. Fac-
tor XIII (FXIII) is a coagulation factor implicated in the
coagulation cascade and its main role is to cross-link ﬁbrin.
FXIII is activated by thrombin and is responsible for the clot
stabilization, for incorporating proteins such as ﬁbronect-
in, thrombospondin and antiﬁbrinolytic protein alpha 2-
antiplasmin, thusmaking thethrombusrelativelymoreresis-
tant to ﬁbrinolysis [67, 68]. The Val34Leu polymorphism
of the FXIII gene has been extensively studied in several
vascular pathologies such as myocardial infarction, venous
thromboembolism and ischemic and hemorrhagic stroke,
butwithcontradictory results.Somereportshaveshown that
the Leu allele is a protective factor for cardiovascular diseases
[69, 70], while others have not conﬁrmed this association
[71, 72]. Focusing on stroke, results are also contradictory.
Some studies indicate that the Leu allele is a risk factor
for hemorrhagic and ischemic stroke [73]w h i l s to t h e r s
could not observe this eﬀect [74, 75]. Regarding throm-
bolytic therapy, patients with the Val/Val genotype presented
lower incidence of SICH than Leu allele carriers. Similarly,
homozygous Val/Val carriers showed lower mortality rates.
Moreover, Val/Val patients with ﬁbrinogen concentrations
lower than 3.6g/L presented mortality rates of 8.8% against
35.7% for the rest of patients. When the neurological deﬁcit
wasevaluated,patientscarrying theLeualleleplusﬁbrinogen
concentrations ≥3.6g/L obtained the highest values on the
NIHSS, indicating worse neurological status [55]( Table 2).
Currently, the Val34Leu polymorphism is the only genetic
variation associated with HT; however new studies with an
increased sample size are required to conﬁrm these results.
Regarding MMP-9, the C1562T polymorphism, which
is located in the promoter region of the MMP-9 gene, has
been described as a factor that could modify MMP9 levels
in vitro. In this study, the T allele conferred an increase in
MMP-9 concentrations due to increased MMP-9 promoter
activity [76]. Also, the T allele has been associated with6 Stroke Research and Treatment
increased concentrations of MMP-9 on diﬀerent pathologies
like coronary artery disease [77], arterial stiﬀness of large
vessels [78] and abdominal aortic aneurysm [79]. Since
MMP-9 levels are associated with HT appearance, it was
hypothesized that this allele could be associated with the
development of this complication in vivo. However, to
date, no association has been demonstrated between this
polymorphism and MMP concentrations or hemorrhagic
complications in humans, probably because this mutation
is not functional in response to cerebral ischemia in vivo or
because of the small sample size [80].
3.2. Genetic Predictors of Recanalization. The angiotensin
converting enzyme (ACE) is an enzyme that belongs to
the renin-angiotensin and the kallikrein-kinin systems. ACE
playsanimportantroleinhypertensionandvasoconstriction
by catalysing the transformation of angiotensin I into angi-
otensin II [81]. Several studies have associated the inhibition
of the renin-angiotensin-aldesterone system with a lower
incidence of ischemic stroke and vascular recurrence (Heart
Outcome Prevention Evaluation (HOPE), Losartan Inter-
vention for Endpoint Reduction in Hypertension Study
(LIFE) and Acute Candesartan Cilexetil Evaluation in Stroke
Survivors (AACESS)). An insertion/deletion (I/D) polymor-
phism in intron 16 of the gene inﬂuences serum enzyme
levels [82]. The D allele homozygous present higher levels
of ACE in serum, and I allele carriers showed lower levels.
The gene has also been linked to PAI-1, in the sense that the
deletion allele was associated with elevated levels of PAI-1
[83, 84], which in turn was associated with recanalization
resistance [61], hence its antiﬁbrinolytic behavior. On the
other hand, the D allele has also been associated with lower
activity of coagulation factors X and VII [85]a n dw i t hl o w
levels of ﬁbrinogen [86], adding an antithrombotic activity.
More recently and accordingly to that, a study showed
that the DD genotype was strongly associated with better
recanalization rates in ischemic stroke treated with rt-PA
(DD = 69.2%, ID + II = 31.6%, P = .002 at 1h; DD = 91.3%,
ID + II = 51%, P = .001 at 6h; DD = 100%, ID + II =
72.3%, P = .003 at 24h post-t-PA administration) without
increasing the odds of bleeding (P = .237) [56]( Table 2).
However, the authors failed to demonstrate an association of
the D allele with PAI-1 or FX and FVII activity.
Regarding TAFI, one of the indirect inhibitors of ﬁbri-
nolysis, a polymorphism in the coding region of the gene
(C1040T) resulting in the Thr325Ile substitution, has been
associated with a 60% increase of TAFI activity [87, 88],
associated with its antiﬁbrinolytic eﬀect. In addition, a study
observed that the presence of the Thr/Ile polymorphism was
associated with lower recanalization rates in combination
with the PAI-1 4G/5G polymorphism [57]. The 4G/5G pol-
ymorphism is located in the promoter region of the PAI-
1 gene. Classically, the 4G allele has been associated with
high levels of PAI-1 in plasma [83, 89]. A large number of
associationstudieshavefocusedonstrokeandcardiovascular
events with contradictory results [40, 90–92]. Referring to
the eﬃcacy of thrombolytic agents, it has been reported
that the combination of 4G allele of PAI-1 gene and Ile/Ile
genotype of TAFI increased the risk of recanalization resis-
tance (OR 11.1 (95% CI 1.4–89.8, P = .025) [57]( Table 2).
The sample size of pharmacogenetic studies is often small.
Similarlytobiomarkersstudies,replicationsofthesigniﬁcant
results obtained should be performed to elucidate the role of
theseSNPsinrt-PAsafetyandeﬃcacy.However,itseemsthat
thereis ageneticsusceptibilitytort-PA response sinceseveral
studies have identiﬁed diﬀerent polymorphisms associated
with rt-PA response. The implementation of these ﬁndings
in the clinical practice will be diﬃcult due to the lack of fast
polymorphisms detection systems.
4.Discussion
Many eﬀorts have been made to identify the biological
and genetic markers that can predict SICH and successful
recanalization after rt-PA infusion, but all the studies present
somemethodologicalissues.Mostofthemusedsmall sample
sizes, which makes it diﬃcult to study SICH (due to its low
prevalence), so they analyzed all types of HT. More studies
focusing only on SICH are needed. Hence, larger samples
sizes are needed to replicate and validate these results. Over
all, biomarkers studies published to date should be regarded
as preliminary studies, since they did not elucidate the
clinical relevance of any single marker or a panel of diﬀerent
markers. Most of these studies were performed with small
samples sizes and the positive predictive values were too
low in most of them. VAP-1/SSAO seems to be a promising
biomarker due to its moderately acceptable positive predic-
tive value. Unfortunately, there is no reliable risk indicator
enabling these high-risk patients to be suﬃciently identiﬁed
yet. The diagnostic accuracy of biomarkers investigated to
date (i.e., matrix metalloproteinase-9, ﬁbronectin, S100B,
VAP-1/SSAO)doesnotappeartobegoodenoughtofunction
as a reliable test in acute stroke management.
Another important issue is how to discern whether the
markers found are related to the HT or to the severity of
stroke itself. MRI studies performed before rt-PA adminis-
tration might help us to elucidate this, by using the infarct
volume before ﬁbrinolytic treatment and the basal NIHSS
as variables in the statistical analysis, and also evaluating the
presence of speciﬁc BBB leakage signs such as hyperintense
acute reperfusion injury as a marker (HARM) [93],
Also further research must be done attempting to ﬁnd
new genes and polymorphisms that explain occurrence of
complication or poor recanalization in order to improve
therapies given to the patients. Findings should also be
replicated and validated in diﬀerent and larger populations.
A more meaningful understanding of gene expression
can be achieved through massive techniques as microarrays
or genome wide association studies (GWASs), since new
genesandtheirproductscouldbediscovered.Itisclear,how-
ever, that all this information although essential, is not suﬃ-
cient. The function of most genes is still unknown, and pro-
teomic studies are now attempting to ﬁll this need. The ulti-
mate phenotype of cells, organs, and organisms is reﬂected
in their instantaneous proteomic proﬁle. Changes in human
states of health are the result of changes in the proteomesStroke Research and Treatment 7
of individual patient overtime and in response to endoge-
nous and/or external stimuli. However, the advent of novel
approaches and large-scale technologies to investigate the
complexity of human disease promises to shed new light
on the pathogenesis of a broad range of diseases, including
stroke and stroke pharmacogenomics. In fact, a very recent
report have shown, for the very ﬁrst time, changes in
protein proﬁles in human stroke brain samples compared
with controls which led to the advent of new proteins that
should be studied in depth to test whether they can be
considered good biomarkers of stroke [94]. Thus it seems
clears that a functional proteomic approach would facilitate
an understanding of signaling pathways in stroke and treat-
ment response that will allow the long-awaited personalized
therapy and also could help to identify new lists of proteins
that could be implicated in rt-PA response and therefore
could be considered and analyzed further as therapeutic
t a r g e t so rn o v e lb i o m a r k e r sf o rr t - P Ar e s p o n s e .
5.Conclusion
Despite recent great advances in basic research considering
the safety and eﬃcacy of rt-PA treatment in stroke patients,
it is still diﬃcult to translate the ﬁndings observed to the
clinicalpractice,andthereisstillalongwaytogobeforethese
ﬁndings can be implemented in hospital settings. Current
technology allows the quantitative detection of proteins in
severalminutes,butthedetectionofrisk polymorphismsina
timely manner after the patient’s arrival to the hospital is still
not possible nowadays. Eﬀorts should thus be made in this
direction, in order to allow rapid screening of the patients,
combining genetic, biochemical and clinical factors, thus
improving the predictive value of these tools and guiding the
clinician’s choice for treatment.
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